ANIP · Ani Pharmaceuticals Inc

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,820 shares of restricted stock, the grant of which was previously reported on July 20, 2022.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.

The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

The shares were sold in multiple trades at prices ranging from $83.39 to $84.63. The price reported above reflects the weighted average sales price.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2026.

The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.

The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

Represents a restricted stock award that will vest in full on May 21, 2027.

Represents a restricted stock award that will vest in full on May 21, 2027.

Represents a restricted stock award that will vest in full on May 21, 2027.

Represents a restricted stock award that will vest in full on May 21, 2027.

Represents a restricted stock award that will vest in full on May 21, 2027.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. The price reported above reflects the weighted average sales price.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

The shares were sold in multiple trades at prices ranging from $70.27 to $72.62. The price reported above reflects the weighted average sales price.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025.

The shares were sold in multiple trades at prices ranging from $72.94 to $74.76. The price reported above reflects the weighted average sales price.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,292 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price.

The shares were sold in multiple trades at prices ranging from $75.41 to $75.56. The price reported above reflects the weighted average sales price.

25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 2,171 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,883 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,040 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,079 shares of restricted stock, the grant of which was previously reported.

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.